Immatics (IMTX) Receivables - Other (2021 - 2023)

Immatics (IMTX) reported Receivables - Other of -$881.3 million for Q4 2023, down 36.47% sequentially from -$645.8 million in Q4 2021.

Immatics (IMTX) Receivables - Other (2021 - 2023) Analysis & Trends

Immatics (IMTX) has 2 years of Receivables - Other data on file, last reported at -$881.3 million in Q4 2023.

For the quarter ending Q4 2023, Receivables - Other changed N/A year-over-year to -$881.3 million; the trailing twelve-month figure through Dec 2023 stood at -$881.3 million (changed N/A YoY), and the FY2025 full-year result was -$1.4 billion, down 322.88% from the prior year.
Receivables - Other declined to -$881.3 million in Q4 2023, from -$645.8 million in the prior quarter.
In the past five years, Receivables - Other ranged from a high of -$645.8 million in Q4 2021 to a low of -$881.3 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immatics	1.14 Bn	1.14 Bn	-

Download Data